International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review
- 1 July 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 19 (4) , 409-420
Abstract
Introduction Orphan diseases are low-prevalence conditions with chronically debilitating or life-threatening consequences. Their treatments are generally called orphan drugs (OD). Health technology assessment processes have traditionally considered cost-effectiveness analysis (CEA), when making reimbursement and pricing decisions for healthcare plans. Valuing OD with standard CEA raises important issues due to uncertain evidence, inability to meet cost-effectiveness thresholds for reimbursement and high budget impact, among others. Multi-criteria decision analysis (MCDA) allows to overcome these issues and improve technical and ethical quality of decisions regarding prioritization, coverage and reimbursement of OD. Areas covered A scoping review was conducted in order to characterize MCDA frameworks for assessing OD and implementation experiences. We reviewed electronic databases (Medline, Embase, Cochrane Library, EBSCO, CINAHL, EconLit, Web of Science, LILACS, Google Scholar) key journals (Orphanet Journal of Rare Diseases and Value in Health) and organization repositories. Expert opinion The theoretical framework for MCDA considers areas related to characteristics of orphan diseases and their technologies’ clinical and economic impact. Participation processes are critical in incorporating societal values in weighting different dimensions and constructing decision rules. Local implementation pilots considering different stakeholders are necessary in order to pinpoint specific barriers and opportunities.Keywords
Funding Information
- Novartis de Colombia (NA)
This publication has 28 references indexed in Scilit:
- Reimbursement of orphan drugs in Belgium: what (else) matters?Orphanet Journal of Rare Diseases, 2014
- Application of a Policy Framework for the Public Funding of Drugs for Rare DiseasesJournal of General Internal Medicine, 2014
- Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the LiteraturePharmacoEconomics, 2014
- Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerationsOrphan Drugs: Research and Reviews, 2014
- A Pilot Study of Multicriteria Decision Analysis for Valuing Orphan MedicinesValue in Health, 2013
- What Is Wrong with Orphan Drug Policies? Suggestions for Ways ForwardValue in Health, 2012
- An Evaluation Framework for Funding Drugs for Rare DiseasesValue in Health, 2012
- Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Orphanet Journal of Rare Diseases, 2012
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applicationsBMC Health Services Research, 2008